Investigating the role of a specific protein in Alzheimer's disease
Role of LRP1 in Alzheimer’s disease
This study is looking at how a protein called LRP1 helps remove harmful substances linked to Alzheimer's, like amyloid-beta and tau, from the brain, and it will also check if things like obesity affect this process, which could help us find new ways to treat Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11023084 on NIH RePORTER |
What this research studies
This research focuses on understanding how low-density lipoprotein receptor-related protein 1 (LRP1) affects the clearance of amyloid-beta and tau proteins in Alzheimer's disease. By studying the cellular mechanisms in the choroid plexus and tanycytes, the research aims to uncover how LRP1 regulates the movement of these proteins from the brain to the bloodstream. The team will explore how factors like obesity may influence this process and contribute to cognitive decline. The findings could lead to new insights into potential therapeutic targets for Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for improving the clearance of harmful proteins in Alzheimer's disease, potentially slowing disease progression.
How similar studies have performed: Previous research has shown promising results in targeting protein clearance mechanisms in Alzheimer's disease, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Kim, Young-Bum — Beth Israel Deaconess Medical Center
- Study coordinator: Kim, Young-Bum
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.